Volinanserin

Из Википедије, слободне енциклопедије
Volinanserin
(IUPAC) ime
(R)-(2,3-dimetoksifenil)-[1-[2-(4-fluorofenil)etil]-4-piperidil]metanol
Klinički podaci
Identifikatori
CAS broj 139290-65-6
ATC kod nije dodeljen
PubChem[1][2] 5311271
ChemSpider[3] 4470782
UNII EW71EE171J YesY
ChEMBL[4] CHEMBL74355
Hemijski podaci
Formula C22H28FNO3 
Mol. masa 373,46 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

Volinanserin (MDL-100,907) je visoko selektivan antagonist 5-HT2A receptor. On je u širokoj upotrebi u naučnim istraživanjima za istraživanje funkcije 5-HT2A receptora.[5][6][7] Volinanserin se isto tako ispituje kao potencijalni antipsihotik, antidepresiv i tretman za insomniju.[8][9][10]

Reference[уреди]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ^ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ^ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining“. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. ^ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery“. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  5. ^ Schmidt CJ, Fadayel GM, Sullivan CK, Taylor VL (November 1992). „5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine“. European Journal of Pharmacology 223 (1): 65–74. DOI:10.1016/0014-2999(92)90819-P. PMID 1362159. 
  6. ^ Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, Rösch F (April 2009). „Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET“. Bioorganic & Medicinal Chemistry 17 (8): 2989–3002. DOI:10.1016/j.bmc.2009.03.021. PMID 19329329. 
  7. ^ Nic Dhonnchadha BA, Fox RG, Stutz SJ, Rice KC, Cunningham KA (April 2009). „Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model“. Behavioral Neuroscience 123 (2): 382–96. DOI:10.1037/a0014592. PMID 19331461. 
  8. ^ Offord SJ, Wong DF, Nyberg S (August 1999). „The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action“. Journal of Clinical Pharmacology Suppl: 17S–24S. PMID 10434243. 
  9. ^ Marek GJ, Martin-Ruiz R, Abo A, Artigas F (December 2005). „The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine“. Neuropsychopharmacology 30 (12): 2205–15. DOI:10.1038/sj.npp.1300762. PMID 15886717. 
  10. ^ Teegarden BR, Al Shamma H, Xiong Y (2008). „5-HT(2A) inverse-agonists for the treatment of insomnia“. Current Topics in Medicinal Chemistry 8 (11): 969–76. DOI:10.2174/156802608784936700. PMID 18673166. 

Vidi još[уреди]

Spoljašnje veze[уреди]